NEW YORK, March 18, 2020 /PRNewswire/ -- AIkido Pharma
Incorporated (Nasdaq: AIKI) today provided an update on the
recently announced Coronavirus technology optioned by the
Company.
"AIkido has been working to move this research forward,"
commented Anthony Hayes, AIkido CEO.
"AIkido is the only company with this option and we are committed
to funding the research in an effort to be part of the solution to
this crisis. The exact amounts of the commitment are
dependent on the research and work needed, which is not a static
figure in the current environment. We understand the need for
information in this uncertain time and we are committed to
providing it as soon as we have it. However, I am sure that you can
understand that the researchers involved are under a tremendous
amount of pressure, and patience is important."
About AIkido
AIkido Incorporated, a Delaware
corporation (the "Company"), was initially formed in 1967 and is
currently a biotechnology company with a diverse portfolio of
small-molecule anti-cancer therapeutics. The Company's
platform consists of patented technology from leading universities
and researchers and we are currently in the process of developing
an innovative therapeutic drug platform through strong partnerships
with world renowned educational institutions, including The
University of Texas at Austin and
Wake Forest University. Our diverse
pipeline of therapeutics includes therapies for pancreatic cancer,
acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL). In addition, we are constantly seeking to grow our pipe to
treat unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its patent business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations: Hayden IR
Brett Maas, Managing
Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
Spherix: Phone: 212-745-1373
Email: investorrelations@spherix.com
www.spherix.com
View original
content:http://www.prnewswire.com/news-releases/shareholder-update-from-aikido-pharma-incorporated-on-coronavirus-option-301026291.html
SOURCE AIkido Pharma Inc.